Acetyl-NF-KB p65 (Lys314/Lys315)抗体;Acetyl-NF-KB p65 (Lys314/Lys315) Antibody—艾普蒂 新品

+ +

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human Breast Carcinoma Tissue using Acetyl-NF-KB p65 (Lys314/Lys315) antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human tonsils using Acetyl-NF-KB p65 (Lys314/Lys315) antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

The Acetyl-NF-κB p65 (Lys314/Lys315) antibody is a specialized tool used to study post-translational modifications of the NF-κB transcription factor, specifically the acetylation of its p65 subunit (also known as RelA) at lysine residues 314 and 315. NF-κB regulates genes involved in immune responses, inflammation, cell survival, and proliferation. Its activity is tightly controlled by multiple post-translational modifications, including phosphorylation, ubiquitination, and acetylation. Acetylation of p65 at Lys314/315. mediated by histone acetyltransferases (HATs) like p300/CBP, plays a critical role in modulating NF-κB transcriptional activity. This modification enhances DNA binding, promotes interaction with co-activators, and reduces binding to inhibitory IκB proteins, thereby prolonging nuclear retention and transcriptional activation of target genes. Conversely, deacetylation by histone deacetylases (HDACs) suppresses NF-κB signaling.

The Acetyl-NF-κB p65 (Lys314/Lys315) antibody is widely used in techniques like Western blotting, immunoprecipitation, and chromatin immunoprecipitation (ChIP) to detect site-specific acetylation events in cellular or tissue samples. Researchers employ this antibody to investigate NF-κB activation dynamics in contexts such as inflammation, cancer, autoimmune diseases, and infections. Its specificity for acetylated Lys314/315 helps dissect the molecular mechanisms linking NF-κB acetylation to disease pathways, offering insights for therapeutic strategies targeting epigenetic regulators or NF-κB signaling. Proper validation via knockout/knockdown controls or peptide competition assays is essential to confirm antibody specificity.